drugset
drugset / Trial / NCT01247350

A Study of LY3009104(Baricitinib) for Healthy Subjects

NCT01247350 ↗

Phase 1 Completed 34 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the safety and tolerability of LY3009104 when given orally as single and multiple doses in Japanese healthy subjects.

Timeline

Start
2010-11
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 2 mg Oral
Subject Baricitinib Small molecule 5 mg Oral
Subject Baricitinib Small molecule 10 mg Oral
Subject Baricitinib Small molecule 14 mg Oral

Indications

No indication recorded.